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Abstract
Background: Intimate links connect tissue factor (TF), the principal initiator of the clotting cascade, to inflammation, a
cross-talk amplified by locally generated Angiotensin (AT) II, the effector arm of the Renin Angiotensin System (RAS).
C21, a selective AT2R agonist, downregulates the transcriptional expression of TF in LPS-activated peripheral blood
mononuclear cell(PBMC)s implying the existence of ATII type 2 receptor (AT2R)s whose stimulation attenuates
inflammation-mediated procoagulant responses. High glucose, by activating key signalling pathways and increasing
the cellular content of RAS components, augments TF expression and potentiates the inhibitory effect of AT1R
antagonists. It is unknown, however, the impact of that stimulus on AT2R-mediated TF inhibition, an information useful
to understand more precisely the role of that signal transduction pathway in the inflammation-mediated coagulation
process. TF antigen (ELISA), procoagulant activity (PCA, 1-stage clotting assay) and TF-mRNA (real-time polymerase
chain reaction) were assessed in PBMCs activated by LPS, a pro-inflammatory and procoagulant stimulus, exposed to
either normal (N) or HG concentrations (5.5 and 50 mM respectively).
Results: HG upregulated TF expression, an effect abolished by BAY 11-7082, a NFκB inhibitor. C21 inhibited LPS-
stimulated PCA, TFAg and mRNA to an extent independent of glucose concentration but the response to Olmesartan,
an AT1R antagonist, was quite evidently potentiated by HG.
Conclusions: HG stimulates LPS-induced TF expression through mechanisms completely dependent upon NFkB
activation. Both AT2R-stimulation and AT1R-blockade downregulate inflammation-mediated procoagulant response in
PBMCs but HG impacts differently on the two different signal transduction pathways.
Keywords: Tissue factor, Thrombosis, Renin angiotensin system, Innate immunity endotoxin, Inflammation, Renin
angiotensin blockers
Background
An extensive cross-talk connects coagulation and in-
flammation [1], a process hinging around Tissue Factor
(TF), the principal initiator of the clotting cascade and a
major regulator of haemostasis and thrombosis rapidly
inducible by inflammatory agents in several cell lines
including monocytes [2]. Activation of NFkB, a key
redox-sensitive transcription factor encoding for the TF
gene [2, 3], plays a key role in that mechanism amplified
by locally synthesized Angiotensin (AT) II [4], the final
effector of the renin angiotensin system (RAS) and an
inflammatory agent on its own [5]. ATII-mediated
stimulation of TF expression has consistently been
shown in monocytes [6], an immunocompetent cell
lineage endowed with the whole biochemical machinery
for the endogenous production of angiotensin (AT)II e.g.
[7–10] as well as ATII type 1 (AT1R) and type 2 (AT2R)
receptors (e.g. [11] eligible for paracrine and/or intracrine
stimulation. In agreement with that concept, AT1R
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antagonists downregulate activated TF expression [12, 13]
among others) but the inhibitory effect of selective AT2R
stimulation [14] is suggestive of the existence of AT2Rs
counteracting the AT1R-mediated procoagulant pheno-
type, as reported for other AT2R-mediated functions [15].
High glucose (HG) concentrations, by accelerating re-
active oxygen species (ROS) generation and increasing
NFkB-induced cytokine production e.g. [16–18], increase
TF expression in human peripheral blood mononuclear
cells (PBMC)s, amplify procoagulant responses in cells
activated by endotoxin (Lipopolysaccharide, LPS) and
potentiate the inhibitory action of RAS blockers includ-
ing AT1R antagonists [13]. However, the influence of
high glucose environment, an experimental condition re-
producing, to some extent, the diabetic state hallmark,
on the TF modulation induced by AT2R agonism is un-
known, a piece of evidence useful to understand in more
detail the role of the AT2R signal transduction pathway
in the inflammation-mediated coagulation process.
For this reason, we investigated the effect of C21, a re-
cently synthesized selective AT2R agonist [19], on TF
expression in human PBMCs exposed to HG and acti-
vated by lipopolysaccharide (LPS, endotoxin), a well
characterized target of the innate immune system [20]
and a procoagulant agent [2]. Olmesartan (OLM), a se-
lective AT1R antagonist [21], was used as a control.
Methods
Cell isolation and culture
Human PBMCs were obtained from unpooled buffy
coats left over from blood bank draws taken from
healthy donors with the approval of the local ethics
committee. According to local procedures, individuals
with a history of diabetes and hypertension, either on
antihypertensive drugs or not, are excluded from blood
donation. As detailed elsewhere [22], leukocytes were
isolated from fresh buffy coats diluted 1:1 with sodium
citrate 0.38 % in saline solution, mixed gently with 0.5
volume of 2 % Dextran T500 and left for 40 min for
erythrocyte sedimentation. The leukocyte-rich super-
natant was recovered and centrifuged for 10 min at
200xg. The pellet was resuspended in 30 ml of sodium
citrate solution, layered over 15 ml of Ficoll-Hypaque
and centrifuged for 30 min at 350xg at 20 °C. The PBMC-
rich ring was recovered, washed twice in sodium citrate
0.38 % and resuspended in no glucose RPMI 1640
medium (Sigma Chemical, St Louis, Missouri, USA)
supplemented with 100 U/ml penicillin-streptomycin.
The final PBMC preparations typically contain 25–
35 % monocytes, 65–75 % lymphocytes and less than
5 % neutrophils [22].
After isolation, cells resuspended in polypropylene
tubes (3×106 cells/ml) were exposed to experimental
drugs or their appropriate vehicle in presence of two
different D-glucose concentrations (5.5 mM, hereafter
referred to as Normal Glucose, NG, or 50 mM hereto-
fore referred to as High Glucose, HG) 30 min prior to
LPS (Escherichia coli 026:B6 LPS; Sigma Chemical),
100 ng/ml, and left to incubate for 18 hs at 37 °C in a
5 % CO2 atmosphere until assay. Previous experiments
had shown the D-glucose concentration-dependent in-
crease in TF procoagulant activity (see below) as well as
the neutral effect of L-Glucose used as a control for
osmolarity changes [13] and, therefore, were not repeated.
Untreated PBMCs were also included in each experimen-
tal series to obtain baseline values. All reagents and solu-
tions used for cell isolation and culture were prepared
with endotoxin-free water and glassware was rendered
endotoxin-free by exposure to high temperature. Drugs
were kept in stock solution and diluted in serum-free
RPMI at the appropriate concentrations immediately be-
fore use. Cell viability as assessed by dimethyl thiazolyl
diphenyl tetrazolium (MTT) was verified (85 % or more of
viable cells) throughout all experimental phases.
Experimental methods
TF procoagulant activity (PCA)
PCA was assessed by a one-stage clotting time test in
PBMCs disrupted by three freeze–thaw cycles, as previ-
ously described [23]. In brief, disrupted cells (100 μl) were
mixed with 100 μl of normal human plasma at 37 °C, add-
ing 100 μl of 25 mmol/l CaCl2 at 37 °C. Time to clot for-
mation was recorded and values converted to arbitrary
units (AU) by comparison with a human brain TF calibra-
tion curve covering clotting times from 20 to 600 s, corre-
sponding to 1000 and 0 AU, respectively. Experiments
were run in triplicate and averaged. As contaminating
platelets may contribute to PCA [24], we performed the
clotting assay in PBMC-free preparations in which PCA
was undetectable (data not shown). Preliminary experi-
ments had also confirmed the procoagulant effect of ATII
(10−6M) added to PBMCs exposed to either NG (from
0.005 ± 0.002 to 0.01 ± 0.006 AU, n = 14, p < 0.01) or HG
(from 0.011 ± 0.007 to 0.02 ± 0.01 AU, n = 10, p < 0.05).
TF antigen (Ag)
Cells were disrupted by three repeated freeze–thaw cycles
and debris pelleted by centrifugation at 100xg for 1 h at
4 °C and supernatants used for ELISA (Imubind TF kit
Sekisui Diagnostics, West Malling, United Kingdom). TF
Ag levels were expressed in pg/ml using a reference curve
created by the TF standards. Within and between assay
variability was 3.5 and 5.5 %, respectively.
TF mRNA
Total RNA was extracted from PBMCs using the RNeasy
mini kit (Qiagen, Hilden, Germany). RNA concentration
and purity were determined by optical density measurement
Balia et al. Journal of Inflammation  (2016) 13:14 Page 2 of 7
via Nanodrop (Thermo Fisher Scientific, Wilmington,
Delaware USA). A mixture of 0.5 ng total RNA per sample
was retro-transcribed with random primer-oligodT into
complementary DNA (cDNA) using the Quantitect Reverse
Transcription Kit (Qiagen, Hilden, Germany). The retro-
transcription cycle was performed at 25 °C for 5 min, 42 °C
for 30 min and 95 °C for 3 min. RealTime-PCR was carried
out in a iQ5 Real Time PCR System and SsoAdvanced Sybr
Green Supermix (Bio-Rad Laboratories, Hercules, CA) was
employed on the basis of the manufacturer’s conditions:
95 °C, 30s; 40 cycles 95 °C, 5 s, 60 °C, 15 s;a final melting
protocol with ramping from 65 °C to 95 °C with 0,5 °C in-
crements of 5 s was performed. The primers sequence for
RealTime-PCR were: TF, sense 5’-TTGGCAAGGACTTA
ATTTATACAC-3’, antisense 5’-CTGTTCGGGAGGGAA
TCAC-3’; GAPDH, sense: 5’-CCCTTCATTGACCTC
AACTACATG-3’ and antisense: 5’-TGGGATTTCCAT
TGATGACAAGC-3’ (Invitrogen, Monza, Italy). All sam-
ples were analysed in duplicate and averaged. The relative
expression of the target gene was normalized to the level of
GAPDH in the same cDNA.
Experimental design
Effect of HG
TF PCA, Ag and mRNA were assessed in resting and
LPS-stimulated PBMCs exposed to either NG or HG.
To evaluate the involvement of NF-kB in that setting,
TF PCA was assessed in LPS-stimulated PBMCs ex-
posed to either NG or HG and pretreated with BAY 11–
7082 (10−5 M Sigma, Milan, Italy), a NF-kB inhibitor
[25], or not.
Effect of AT2R agonism by C21 and AT1R blockade by OLM
Either C21, a selective AT2R agonist [19], or OLM, a se-
lective AT1R antagonist [20], were added at log-increasing
steps (10−8-10−5 M for both) to LPS-activated PBMCs in-
cubated in either NG or HG media.
Effect of AT2R antagonism
To confirm its AT2R selectivity, C21 was added at log-
increasing steps (10−8-10−5 M) to LPS-activated PBMCs
incubated in NG or HG media in absence or presence of
PD123,319 (10−6 M, di(trifluoroacetate) salt hydrate,
Sigma Milan, Italy), a selective AT2R antagonist [26].
Statistics
Statistical differences were assessed by non parametric
tests (Wilkoxon’s and Mann-Whitney for paired and un-
paired comparisons respectively) on either absolute data
or percent changes from control conditions, these latter
taken as a measure of drug effect. Data were reported as
means ± SD unless otherwise reported. A two-tailed p-
level <0.05 was the threshold for statistical significance.
Results
Effect of HG on TF expression
Resting and LPS-stimulated TF PCA, Ag and mRNA
were greater in HG than NG (Table 1). In both experi-
mental conditions, BAY 11-7082 (10−5M) abolished
LPS-stimulated PCA (Fig. 1).
Effect of HG on C21 and OLM
Both C21 and OLM downregulated LPS-induced TF
PCA (Fig. 2). However, the extent of inhibition exerted
by C21 was by and large not influenced by D-glucose
concentrations (Fig. 2, left panel) in contrast with OLM
whose effect was potentiated in HG (Fig. 2, right panel).
A similar behaviour was found when analyzing the ef-
fect of the two drugs on TFAg and TFmRNA (Fig. 3, left
and right panel respectively).
Effect of AT2R antagonism
PD123,319 (10−6M) abolished the effect of C21 in both
NG and HG (Fig. 4, left and right panel respectively).
Discussion
Background of the study
The interpretation of the results of this study are facili-
tated by some further discussion of the involvement of
ATII in innate immunity, a biological system by which
germline-encoded receptor proteins recognize specific
patterns presented by groups of pathogens [20]. Among
them, LPS, the proinflammatory stimulus used in our
experimental series, constitutes a major marker for the
recognition of intruding Gram-negative bacteria that, by
binding to Toll-like receptor(TLR)4 s and CD14 and
recruiting adaptor proteins to the cytoplasmic Toll/inter-
leukin-1 receptor, initiates the pathogen-induced inflam-
matory response of which activation of coagulation is a
prominent component [1, 20]. ATII contributes to the
Table 1 Resting and LPS(100 ng/ml)-stimulated Tissue Factor
(TF) procoagulant activity (PCA), antigen(ag) and mRNA in




Resting 0.0054 ± 0.003 0.035 ± 0.4*
LPS-stimulated (N = 33) 0.93 ± 0.36** 2.7 ± 1.1*, **
TFAg (ng/mL)
Resting 32 ± 24 428 ± 135*
LPS-stimulated (N = 12) 1486 ± 388** 2652 ± 622*, **
TF mRNA (normalized fold expression)
Resting 0.007 ± 0.003 0.158 ± 0.1*
LPS-stimulated (N = 8) 0.65 ± 0.5** 0.85 ± 0.5*, **
*p < 0.001 HG vs NG, **p < 0.001 LPS- stimulated vs resting
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innate immune response through complex and interre-
lated transcriptional and posttranscriptional mechanisms
including upregulation of the TLR4 expression leading to
a more intense NF-kB activation e.g. [27–29]. In turn, LPS
or its intracellular proxies such as TNF-alpha [20] stimu-
late ATII generation [30] by activating renin, the earlier
step of its biosynthetic chain [31], and increasing the
number of ATII receptors available for stimulation by the
peptide [32]. Thus, immunomodulation appears as an in-
tegral component of RAS functions far away from the
conventional view of a hormonal system mainly involved
in systemic blood pressure and body fluid volume control.
Although primarily aimed at the acute defence against
infection and tissue damage, a growing body of evidence
implicates innate immunity in several chronic conditions
including type 2 diabetes [33] in which raised glucose
concentrations, the hallmark of that disease, induce
overexpression of Toll-like receptor(TLR) [34, 35] and
CD14 [36], promote de-novo local synthesis of RAS
components [37, 38] and potentiate a wide array of
ATII-mediated biological actions e.g. [39–41]. By stimu-
lating NADPH oxidase and mitochondrial metabolism,
HG also accelerates reactive oxygen species (ROS) gen-
eration activating NFkB [16–18], thus initiating TF gene
transcription along with a host of other proinflammatory
cytokines. That concept is fully in line with our results
showing upregulation by HG of both quiescent and
LPS-induced TF PCA, mRNA and Ag expression and
abolition of activated PCA by BAY11-7082, a NF-kB in-
hibitor [25], demonstrates the complete dependency
upon the NFkB signalling pathway of the procoagulant
effect of endotoxin in human PBMCs.
HG and AT2R agonism on LPS-stimulated TF expression
Within the frame of reference summarized in the previous
paragraph, our data confirm the inhibitory action of AT2R
agonism by C21 on LPS-stimulated TF expression in hu-
man PBMCs [14] and the complete antagonism exerted
by PD123,319 reassures about the specificity of the re-
sponse. The parallel decrease of TFAg and mRNA is con-
sonant with transcriptional modulation of TF protein
likely by NFkB downregulation [41], an interpretation fully
supported by recent reports showing attenuated cytokine
production by C21 in LPS-stimulated monocytic cells
Fig. 1 Abolition by BAY11-7082 (10−5M), a NF-kB inhibitor [23], of
LPS-induced Tissue Factor procoagulant activity (TFPCA) in both
normal (NG, 5.5 mM) and high (HG, 50 mM) glucose conditions.
Note the different scale of the left and right ordinate. Means ± SD,
n = 7 per group
Fig. 2 Concentration-dependent downregulation of LPS (100 ng/ml)-induced Tissue Factor procoagulant activity by C21 (left panel) and
olmesartan (right panel) in normal (NG,♦, 5.5 mM) and high (HG,○, 50 mM) glucose conditions. N = 12 experiments each, !p < 0.001 vs vehicle,
*p < 0.01 HG vs NG. For the sake of clarity, the graphs report only mean values
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[42]. In addition to those relevant albeit confirmatory find-
ings, however, the main and original pathophysiological
implications of this study arise from the contrast between
the neutral effect of HG on C21-induced TF inhibition
and the potentiated effect of AT1R blockade by OLM in
PBMCs exposed to high D-glucose. That divergent behav-
iour, in fact, indicates that HG impacts differently on
AT1R- and AT2R-mediated signal transduction pathways
although our data do not allow any obvious explanation
for that divergence. On a speculative basis, increased
AT1Rs available for binding as a consequence of higher
D-glucose concentrations [32] might potentiate the effect
of OLM although the same should theoretically apply to
AT2R stimulation given the sensitivity of that receptor
subset to glucose concentrations [43]. The greater inhibi-
tory effect of OLM might also relate to increased ANGII
production in PBMCs grown in HG media [37, 38]
although AT2R antagonism by PD 123, 329 per se was to-
tally neutral on the procoagulant potential of PBMCs in
our previous experience [14]. Thus, TF inhibition by C21
may merely represent the result of a pharmacological ma-
nipulation of physiologically silent binding sites activated
by an agonist attaining concentrations at the receptor site
far exceeding those achieved by ATII, the endogenous lig-
and [44]. Other mechanisms peculiar to AT1R blockers
may also be at play including modulation of TLR4 expres-
sion and activity possibly independent of AT1R blockade
[45] but this as well as all the above outlined possibilities
are speculative and our data cannot provide any solid evi-
dence in favour or against them.
Conclusion
This study confirms the stimulating property of HG on
resting and activated procoagulant activity and demonstrate
Fig. 3 Downregulation of LPS(100 ng/ml)-induced TFAg (Left panel) and mRNA (Right panel) expression by C21 (10−5M) and olmesartan (OLM, 10
−5M) in normal (NG, black bars, 5.5 mM) and high (HG, gray bars, 50 mM) glucose conditions. Means ± SD, at least n = 7 experiments per series, !
p < 0.001 vs. vehicle; *p < 0.001 HG vs NG
Fig. 4 Antagonism by PD123,319 (○,10−6M), a selective AT2R blocker [26], of C21-mediated inhibition (♦) of LPS(100 ng/ml)-induced Tissue Factor
procoagulant activity in normal (left panel, NG, 5.5 mM) and high (right panel, HG, 50 mM) glucose conditions. Mean ± SD, n = 6 experiments per
group. ! p < 0.001 vs. vehicle; *p < 0.001 C21 (♦) vs C21+ PD123,319 (○)
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the obligatory role of NFkB in mediating the procoagulant
effect of LPS in human PBMNCs. In addition, we showed
the neutral effect of HG on the TF-inhibiting effect of C21,
a selective AT2R agonist, quite in contrast with the potenti-
ated effect of OLM under the same experimental condi-
tions, a divergent behaviour indicating that HG impacts
differently on AT1R- and AT2R-mediated signal transduc-
tion pathways. However, further work is needed to under-
stand the precise determinants of the phenomenon more
precisely and the extent to which in-vitro data can be trans-
ferred to in-vivo conditions.
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